Although the National Health Insurance Service (NHIS) has conducted a reevaluation on immunotherapies listed for reimbursement, the government agency decided to keep the outcome undisclosed.

On the contrary, the Health Insurance Review and Assessment Service (HIRA) disclosed the outcome of a consignment research done with the same topic. The NHIS’ decision to conceal the outcome has stirred up the relevant industries in South Korea.

On Feb. 10, the pharmaceutical and medical industry associates told NHIS has recently injected approximately 250 million won for a year-long research on clinical evidence-based reevaluation on listed immunotherapies, but decided to keep the outcome to them